__timestamp | Iovance Biotherapeutics, Inc. | TG Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 9335772 | 24518692 |
Thursday, January 1, 2015 | 12390000 | 19886580 |
Friday, January 1, 2016 | 25602000 | 12631689 |
Sunday, January 1, 2017 | 21262000 | 21977998 |
Monday, January 1, 2018 | 28430000 | 20759000 |
Tuesday, January 1, 2019 | 40849000 | 20838000 |
Wednesday, January 1, 2020 | 60210000 | 121812000 |
Friday, January 1, 2021 | 83664000 | 152137000 |
Saturday, January 1, 2022 | 104097000 | 83231000 |
Sunday, January 1, 2023 | 106916000 | 122706000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing expenses is crucial for success. Over the past decade, TG Therapeutics, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, TG Therapeutics saw a remarkable increase of approximately 400% in their SG&A expenses, peaking in 2021. This surge reflects their aggressive expansion and investment in administrative capabilities. Meanwhile, Iovance Biotherapeutics experienced a steady rise, with a notable 100% increase from 2018 to 2023, indicating a more measured approach to scaling operations. These trends highlight the strategic differences between the two companies, with TG Therapeutics focusing on rapid growth and Iovance maintaining a steady course. As the biotech industry continues to evolve, understanding these financial strategies provides valuable insights into the future trajectories of these innovative firms.
Breaking Down SG&A Expenses: Johnson & Johnson vs TG Therapeutics, Inc.
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?